John Jacobs, Novavax CEO
February 28, 2023 05:35 PM ESTUpdated March 3, 04:11 AM
Pharma

Strug­gling No­vavax de­tails a wave of red ink and plots sur­vival course af­ter rais­ing 'go­ing con­cern' alert

John Carroll

Editor & Founder

No­vavax’s slow windup for its Covid-19 vac­cine pitch has cre­at­ed a per­ilous stretch ahead for the long­time vac­cine play­er. Af­ter the mar­ket closed on Tues­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times